Silver Creek Pharmaceuticals
Tuesday, June 04, 2024
Company Presentation
![CNS/Neurological](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 1
Silver Creek is a clinical-stage biotechnology company headquartered in San Francisco, CA. Our Smart Growth Factorâ„¢ technology enables the rapid development of growth factor fusion proteins that are designed to target and heal damaged tissues. Our lead asset, scp776, is a first-in-class, targeted fusion protein that harnesses the cell survival function of IGF-1. Scp776 is currently being evaluated in ARPEGGIO, a Phase II study for the treatment of acute ischemic stroke.
![Silver Creek Pharmaceuticals](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1799169-1-JPG.jpg)
Company Website:
https://silvercreekpharma.com/
Lead Product in Development:
scp776
Company HQ City
San Francisco
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Mark Corrigan, MD
Development Phase of Primary Product
Phase II
Primary Speaker